News

Anixa Biosciences: Oncology Platform With Asymmetric Upside
Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...
Astria: Betting On Navenibart In The Crowded HAE Arena
Astria Therapeutics ( NASDAQ: ATXS) is a Boston-based pre-commercial biotech developing two late-stage candidates (Navenibart and STAR-0310). The company was initially known as Catabasis ...
Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery ...
Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...